File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Natural killer cell therapy in children with relapsed leukemia

TitleNatural killer cell therapy in children with relapsed leukemia
Authors
KeywordsNK cell
Relapse
Cell therapy
Childhood leukemia
Issue Date2015
Citation
Pediatric Blood and Cancer, 2015, v. 62, n. 8, p. 1468-1472 How to Cite?
Abstract© 2015 Wiley Periodicals, Inc. Background: Novel therapies are needed for children with relapsed or refractory leukemia. We therefore tested the safety and feasibility of haploidentical natural killer cell therapy in this patient population. Procedure: Twenty-nine children who had relapsed or refractory leukemia were treated with chemotherapy followed by the infusion of haploidentical NK cells. Cohort 1 included 14 children who had not undergone prior allogeneic hematopoietic cell transplantation (HCT), whereas Cohort 2 included 15 children with leukemia that had relapsed after HCT. Results: Twenty-six (90%) NK donors were KIR mismatched (14 with one KIR and 12 with 2 KIRs). The peak NK chimerism levels were >10% donor in 87% of the evaluable recipients. In Cohort 1, 10 had responsive disease and 12 proceeded to HCT thereafter. Currently, 5 (36%) are alive without leukemia. In Cohort 2, 10 had responsive disease after NK therapy and successfully proceeded to second HCT. At present, 4 (27%) are alive and leukemia-free. The NK cell infusions and the IL-2 injections were well-tolerated. Conclusions: NK cell therapy is safe, feasible, and should be further investigated in patients with chemotherapy-resistant leukemia.
Persistent Identifierhttp://hdl.handle.net/10722/294506
ISSN
2020 Impact Factor: 3.167
2015 SCImago Journal Rankings: 1.505
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorRubnitz, Jeffrey E.-
dc.contributor.authorInaba, Hiroto-
dc.contributor.authorKang, Guolian-
dc.contributor.authorGan, Kwan-
dc.contributor.authorHartford, Christine-
dc.contributor.authorTriplett, Brandon M.-
dc.contributor.authorDallas, Mari-
dc.contributor.authorShook, David-
dc.contributor.authorGruber, Tanja-
dc.contributor.authorPui, Ching Hon-
dc.contributor.authorLeung, Wing-
dc.date.accessioned2020-12-03T08:22:53Z-
dc.date.available2020-12-03T08:22:53Z-
dc.date.issued2015-
dc.identifier.citationPediatric Blood and Cancer, 2015, v. 62, n. 8, p. 1468-1472-
dc.identifier.issn1545-5009-
dc.identifier.urihttp://hdl.handle.net/10722/294506-
dc.description.abstract© 2015 Wiley Periodicals, Inc. Background: Novel therapies are needed for children with relapsed or refractory leukemia. We therefore tested the safety and feasibility of haploidentical natural killer cell therapy in this patient population. Procedure: Twenty-nine children who had relapsed or refractory leukemia were treated with chemotherapy followed by the infusion of haploidentical NK cells. Cohort 1 included 14 children who had not undergone prior allogeneic hematopoietic cell transplantation (HCT), whereas Cohort 2 included 15 children with leukemia that had relapsed after HCT. Results: Twenty-six (90%) NK donors were KIR mismatched (14 with one KIR and 12 with 2 KIRs). The peak NK chimerism levels were >10% donor in 87% of the evaluable recipients. In Cohort 1, 10 had responsive disease and 12 proceeded to HCT thereafter. Currently, 5 (36%) are alive without leukemia. In Cohort 2, 10 had responsive disease after NK therapy and successfully proceeded to second HCT. At present, 4 (27%) are alive and leukemia-free. The NK cell infusions and the IL-2 injections were well-tolerated. Conclusions: NK cell therapy is safe, feasible, and should be further investigated in patients with chemotherapy-resistant leukemia.-
dc.languageeng-
dc.relation.ispartofPediatric Blood and Cancer-
dc.subjectNK cell-
dc.subjectRelapse-
dc.subjectCell therapy-
dc.subjectChildhood leukemia-
dc.titleNatural killer cell therapy in children with relapsed leukemia-
dc.typeArticle-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1002/pbc.25555-
dc.identifier.pmid25925135-
dc.identifier.pmcidPMC4634362-
dc.identifier.scopuseid_2-s2.0-84932195488-
dc.identifier.volume62-
dc.identifier.issue8-
dc.identifier.spage1468-
dc.identifier.epage1472-
dc.identifier.eissn1545-5017-
dc.identifier.isiWOS:000356867200024-
dc.identifier.issnl1545-5009-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats